Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT, Nimotuzumab, and Tislelizumab for Oligoprogressive NPC
NCT06676722Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab, tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Xiamen University. Started Nov 2024; status: recruiting.
02
Drugs
nimotuzumabtislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06676722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676722.